Metastases to the brain remain a significant problem in lung cancer, as treatment by most
small-molecule targeted therapies is severely limited by efflux transporters at the blood …

Brain metastases (BM) are common and disastrous occurrence in patients with non-small
cell lung cancer (NSCLC). Currently increasing studies suggest remarkable efficacy and …

Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)
mutations commonly present brain metastases (BM) at the time of NSCLC diagnosis or …

Leptomeningeal metastasis (LM) is a terminal event in the development of non-small cell
lung cancer (NSCLC). It has a poor prognosis with median survival of 1.9 months if …

The epidermal growth factor receptor (EGFR) is genetically altered in nearly 60% of
glioblastoma tumors; however, tyrosine kinase inhibitors (TKIs) against EGFR have failed to …

The clinical efficacy of gefitinib, a tyrosine kinase inhibitor of epidermal growth factor
receptor (EGFR), on brain metastases (BMs) from non–small-cell lung cancer (NSCLC) was …

Background Chemotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors are controversial in the treatment of patients with brain metastases from non-small …

Purpose Several cases have been reported in which central nervous system (CNS)
metastases of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by …

Results Fifteen BM patients completed gefitinib plus WBRT. The CSF-to-plasma ratio of
gefitinib in patients with BM was higher than that in patients without BM (1.34% vs. 0.36 …

Background: The significance of uncommon epidermal growth factor receptor (EGFR)
mutations in patients with non-small cell lung cancer (NSCLC) and brain metastasis (BM) …